Unawareness of Primary Aldosteronism as a Common Cause of Hypokalemia – Insights from the IPAHK⁺ Trial (Incidence of Primary Aldosteronism in Patients with Hypokalemia)

Abstract

Hypokalemia plays an important role in the diagnosis and management of primary aldosteronism (PA). While the hypokalemic variant of the disease accounts for about one third of all cases, little is known about the incidence of PA in hypokalemic populations. The IPAHK+ study is an epidemiological, cross-sectional trial to provide evidence on the incidence of PA in hypokalemic patients from a university hospital outpatient population. Recruitment of outpatients with hypokalemia≤3 mmol/l is carried out on a continuous referral-basis through an automated data delivery system. Up to an interim data closure, 66 patients underwent the study protocol. The mean age of the participants was 52.9±1.5 years with an equal sex ratio of 1:1 women to men, a mean potassium value of 2.78±0.31 mmol/l [1.8;3.0] and a prevalence of arterial hypertension of 72.7%. PA was diagnosed in 46.6% of all participants, all of whom had a history of hypertension. Incidence of PA increased continuously with decreasing potassium levels with proportions of 26.7%, 50% and 57.1% in the subgroups of 3.0 mmol/l (n=15), 2.8–2.9 mmol/l (n=22) and≤2.7 mmol/l (n=21), respectively. Prior to testing, 59.1% of all patients presented at least with one plausible other cause of hypokalemia. The incidence of PA in the investigated outpatient population was more than 4 out of 10 and inversely correlated with baseline potassium levels. Moderate or severe hypokalemia, regardless of its cause, should therefore prompt evaluation for PA in hypertensive individuals. Normotensive hypokalemic PA was not observed in this cohort.

Key words

primary aldosteronism - hypokalemia - potassium

Publikationsverlauf

Eingereicht: 29. August 2023

Angenommen nach Revision: 04. November 2023

Accepted Manuscript online:
04. November 2023

Artikel online veröffentlicht:
11. Dezember 2023

• References

• 1 Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019; 285: 126-148
• 2 Hannemann A, Bidlingmaier M, Friedrich N. et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012; 167: 7-15
• 3 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 4 Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e15985
• 5 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
• 6 Rossi E, Perazzoli F, Negro A. et al. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000-2015). J Hypertens 2017; 35: 1691-1697
• 7 Mulatero P, Stowasser M, Loh KC. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050
• 8 Gruber S, Stasi E, Steiner R. et al. Incidence of primary aldosteronism in patients with hypokalemia (IPAHK+): study design and baseline characteristics. Horm Metab Res 2021; 53: 787-793
• 9 Arroyo JP, Ronzaud C, Lagnaz D. et al. Aldosterone paradox: differential regulation of ion transport in distal nephron. Physiology (Bethesda) 2011; 26: 115-123
• 10 Born-Frontsberg E, Reincke M, Rump LC. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
• 11 Cannavo A, Bencivenga L, Liccardo D. et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev 2018; 2018: 1204598
• 12 Stowasser M, Ahmed AH, Pimenta E. et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-176
• 13 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
• 14 Krogager ML, Torp-Pedersen C, Mortensen RN. et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J 2017; 38: 104-112
• 15 Gruber S, Beuschlein F. Hypokalemia and the prevalence of primary aldosteronism. Horm Metab Res 2020; 52: 347-356
• 16 Hundemer GL, Imsirovic H, Vaidya A. et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension 2022; 79: 178-186
• 17 Burrello J, Monticone S, Losano I. et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 2020; 75: 1025-1033
• 18 Monticone S, D’Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
• 19 Krishna GG. Effect of potassium intake on blood pressure. J Am Soc Nephrol 1990; 1: 43-52
• 20 Binia A, Jaeger J, Hu Y. et al. Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure: a meta-analysis of randomized controlled trials. J Hypertens 2015; 33: 1509-1520